Pfizer (PFE) will share a portion of increased revenue from higher drug prices abroad with the US Department of Health and Human Services under a contract tied to the Trump administration's "most favored nation" pricing policy, according to newly released documents obtained by Public Citizen.

The deal with Pfizer runs through Jan. 20, 2029, the consumer advocacy group said.

The contract says HHS will use the funds to lower costs for US patients and taxpayers, without specifying more details.

Pfizer and the White House did not immediately respond to MT Newswires' request for comment.